Next 10 |
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci,...
2024-03-06 13:52:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Passage Bio (NASDAQ: PASG ) just reported results for the fourth quarter of 2023. Passage Bio reported earnings per share of -30 cents. This was above the analyst estimate...
$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 26 for the initial award in the fall of 2024 PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Pas...
Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven global sites now activated Pursuing new indications for PBFT02, including adult neurod...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferen...
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will partici...
2023-12-20 14:20:15 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio For further details see: Passage Bio stock climbs 9% on dementia study, program up...
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatment Elevated progranulin levels were sustained at up to six months post-treatment Dose 1 of PBFT02 was generally well-tolerated in patients who re...
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passa...
News, Short Squeeze, Breakout and More Instantly...
Passage Bio Inc. Company Name:
PASG Stock Symbol:
NASDAQ Market:
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci,...
$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 26 for the initial award in the fall of 2024 PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Pas...